REMARKS

Favorable reconsideration of the application as currently amended and in view of the following remarks, is respectfully requested.

Claims 9-13 and 17 are currently pending in the application. Claims 9-13 have been amended to depend from independent Claim 17. Claims 14-16 have been canceled and have been replaced by new Claim 17. Support for Claim 17 can be found on at least page 10, lines 8-25 of the specification. No new matter has been added.

By way of summary, Claims 9-12 and 14-16 were rejected under 35 U.S.C. § 103(a) as being unpatentable over <u>Goesele et al.</u> (US 6,150,239, hereinafter "<u>Goesele</u>") in view of <u>Usenko</u> (US 6,995,075). Claim 13 was rejected under 35 U.S.C. § 103(a) in view of <u>Goesele</u> and in view of <u>Usenko</u> and further in view of <u>Maleville et al.</u> (US 6,403,450, hereinafter "<u>Maleville</u>").

Turning to the rejection of Claims 9-12 and 14-16 under 35 U.S.C. § 103(a) as being unpatentable over <u>Goesele</u> in view of <u>Usenko</u>, the Official Action (page 3) takes the position that <u>Goesele</u> does not disclose a step of thinning down the thin film transferred onto a target substrate. To overcome this deficiency in <u>Goesele</u>, the Official Action (page 3) turns to <u>Usenko</u> for this feature. In addition, the Official Action (page 3) states that while <u>Goesele</u> does "not use the same verbiage regarding the determination of the acceptor defects, in order that the number of accepted defects is compatible with the desired electrical properties of the thin film, this [sic, that the determination of acceptor defects] constitutes routine optimization of process parameters to achieve a result."

New Claim 17 specifies that the initial substrate is made of SiC and that the implantation conditions allow the obtaining of a defect concentration in the first 500 nm of implanted SiC which is lower than 9.10²⁰ atoms/cm³. These conditions obtain in the thin film layer, thinned to a thickness lower than 500 nm, an acceptable number of defects. According

to the invention, keeping the defect concentration under a threshold along a required thickness of implanted SiC obtains a transferred thin film presenting required electrical properties.

Neither <u>Goesele</u> nor <u>Usenko</u> suggest the precise threshold as recited in Applicants' claims. Consequently, neither <u>Goesele</u> nor <u>Usenko</u> disclose the precise threshold in association with a thinning step of the initial substrate. Accordingly, Applicants believe that Claim 17, as currently amended, is not taught or suggested by the combined teachings and suggestions of <u>Goesele</u> and <u>Usenko</u>.

Turning next to the rejection of Claim 13 under 35 U.S.C. § 103 as unpatentable over Goesele in view of <u>Usenko</u> and <u>Maleville</u>, this rejection should be withdrawn because there is nothing in the Official Action to indicate that <u>Maleville</u> would overcome the basic deficiencies of the basic combination to <u>Goesele</u> and <u>Usenko</u> and because Claim 13 depends from Claim 17.

From all of the above, Claims 9-13 and 17 are considered to be in condition for allowance. An early indication to that effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Bradley D. Lytle

Registration No. 40,073

Attorney of Record

Stuart S. Levy

Registration No. 61,474

Customer Number 22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 08/07)

I:\ATTY\SSL\26\263\263098US-AM.DOC